Production (Stage)
Seres Therapeutics, Inc.
MCRB
$7.05
-$0.04-0.56%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 309.00% | -117.61% | 370.08% | 18.10% | 2.70% |
| Total Depreciation and Amortization | -89.54% | 632.55% | -1.13% | -8.92% | -85.20% |
| Total Amortization of Deferred Charges | -- | -100.00% | -4.54% | 4.30% | 13.69% |
| Total Other Non-Cash Items | 242.89% | 97.06% | -1,585.43% | -35.22% | 767.00% |
| Change in Net Operating Assets | 61.12% | -214.04% | 42.34% | -81.77% | 40.52% |
| Cash from Operations | 169.21% | -12.12% | 12.89% | -12.98% | 25.82% |
| Capital Expenditure | 62.22% | 30.23% | -30.30% | -59.68% | 92.93% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -100.00% | -- | -- | -- |
| Other Investing Activities | -- | -- | -100.00% | -- | -- |
| Cash from Investing | 62.22% | -100.06% | 10,740.48% | 2,200.00% | 92.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -- | -- | -- |
| Issuance of Common Stock | -32.07% | -89.80% | -- | -100.00% | 191.83% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -32.07% | 101.57% | -- | -100.00% | 191.83% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 175.35% | -744.74% | 88.55% | -132.88% | 60.58% |